The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline

Taisei Wake, Hajime Tabuchi, Kei Funaki, Daisuke Ito, Bun Yamagata, Takahito Yoshizaki, Masashi Kameyama, Tadaki Nakahara, Koji Murakami, Masahiro Jinzaki, Masaru Mimura

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalInternational Psychogeriatrics
DOIs
Publication statusAccepted/In press - 2017 Nov 2

Fingerprint

Disclosure
Amyloid
Psychology
Positron-Emission Tomography
Anxiety
Depression
Safety
Dementia
Cognitive Dysfunction
Japan
Clinical Trials
Population

Keywords

  • Alzheimer disease
  • biomarkers
  • ethics
  • memory clinics
  • positron emission tomography (PET)

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

@article{014c68b1a4af48b3a4094c6894013c0f,
title = "The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline",
abstract = "In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.",
keywords = "Alzheimer disease, biomarkers, ethics, memory clinics, positron emission tomography (PET)",
author = "Taisei Wake and Hajime Tabuchi and Kei Funaki and Daisuke Ito and Bun Yamagata and Takahito Yoshizaki and Masashi Kameyama and Tadaki Nakahara and Koji Murakami and Masahiro Jinzaki and Masaru Mimura",
year = "2017",
month = "11",
day = "2",
doi = "10.1017/S1041610217002204",
language = "English",
pages = "1--5",
journal = "International Psychogeriatrics",
issn = "1041-6102",
publisher = "Cambridge University Press",

}

TY - JOUR

T1 - The psychological impact of disclosing amyloid status to Japanese elderly

T2 - a preliminary study on asymptomatic patients with subjective cognitive decline

AU - Wake, Taisei

AU - Tabuchi, Hajime

AU - Funaki, Kei

AU - Ito, Daisuke

AU - Yamagata, Bun

AU - Yoshizaki, Takahito

AU - Kameyama, Masashi

AU - Nakahara, Tadaki

AU - Murakami, Koji

AU - Jinzaki, Masahiro

AU - Mimura, Masaru

PY - 2017/11/2

Y1 - 2017/11/2

N2 - In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

AB - In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

KW - Alzheimer disease

KW - biomarkers

KW - ethics

KW - memory clinics

KW - positron emission tomography (PET)

UR - http://www.scopus.com/inward/record.url?scp=85033382300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033382300&partnerID=8YFLogxK

U2 - 10.1017/S1041610217002204

DO - 10.1017/S1041610217002204

M3 - Article

C2 - 29094656

AN - SCOPUS:85033382300

SP - 1

EP - 5

JO - International Psychogeriatrics

JF - International Psychogeriatrics

SN - 1041-6102

ER -